U.S. FDA finds violations at Novo’s main U.S. plant in May 2022

Back in May last year, U.S. drug regulators published a report detailing quality control violations at Novo Nordisk’s main North American plant, according to a statement obtained by Reuters through the Freedom of Information Centre.

Share This Post: